Published as

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

Annie M Young PGCSR, Lucinda J Billingham PhD, Gulnaz Begum BSc, Prof David J Kerr DSc, Ana I Hughes BSc, Daniel W Rea PhD, Stephen Shepherd MD, Andrew Stanley MPhil, Ann Sweeney MSc, Jonathan Wilde MD, Prof Keith Wheatley PhD, on behalf of the WARP Collaborative Group, UK

The Lancet - 14 February 2009 (Vol. 373, Issue 9663, Pages 567-574)

DOI: 10.1016/S0140-6736(09)60205-1

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60205-1/abstract
REPORT OF A RANDOMISED TRIAL OF THROMBOPROPHYLAXIS
WITH WARFARIN IN CANCER PATIENTS
WITH CENTRAL VENOUS CATHETERS: ‘WARP’

Authors: Young AM¹, Billingham LJ¹, Begum G¹,², Kerr DJ³, Hughes AI¹, Rea DW¹, Shepherd S⁴, Stanley A⁵, Sweeney A¹, Wilde J⁶, Wheatley K⁷ on behalf of the WARP Collaborative Group, UK

¹Cancer Research UK Clinical Trials Unit, University of Birmingham, UK
²Warwick Medical School Clinical Trials Unit, University of Warwick, UK
³Oncology Clinical Trials Office, University of Oxford, UK
⁴Gloucestershire Oncology Centre, Cheltenham General Hospital, UK
⁵City Hospital, Birmingham, UK
⁶Queen Elizabeth Hospital, Birmingham, UK
⁷Birmingham Clinical Trials Unit, University of Birmingham, UK

Corresponding author:

Annie Young
Cancer Research UK Clinical Trials Unit
Institute for Cancer Studies
University of Birmingham
Birmingham, B15 2TT

E-mail a.young@bham.ac.uk

Acknowledgements: Medical Research Council, Cancer Research UK

ISRCTN: 50312145
SUMMARY

Background: The role and dose of anticoagulants in thrombosis prophylaxis for cancer patients with central venous catheters (CVCs) is controversial.

Methods: 1590 cancer patients receiving chemotherapy via CVCs were randomised to no warfarin [control] vs warfarin [either daily fixed dose 1mg warfarin (FDW) or daily dose adjusted warfarin (DAW) to maintain International Normalised Ratio between 1.5 and 2.0]. Clinicians ‘certain’ of the benefit of warfarin randomised between FDW and DAW. The primary outcome measure is the incidence of radiologically proven, symptomatic catheter-related thrombosis (CRT); secondary outcome measures include toxicity, incidence of all thromboses and overall survival.

Findings: Compared to control, warfarin (79% FDW; 21% DAW) reduced neither CRT [5.9% vs 5.9%; relative risk (RR) 0.99, (95% Confidence Interval (CI) 0.57-1.72), p=0.98] nor all thrombotic events [7.4% vs 9.4%; RR 0.78 (95%CI 0.50-1.24), p=0.30]. However, compared to FDW only, DAW was superior in preventing CRT [2.8% vs 7.2%; RR 0.38, (95%CI 0.20-0.71), p=0.002] but not all thromboses [5.5% vs 7.9%; RR 0.70 (95%CI 0.43-1.14), p=0.15]. Major bleeding events were rare; an excess was observed with warfarin compared to control (7 vs 1, p=0.07) and with DAW compared to FDW (16 vs 7, p=0.09). A combined endpoint of thromboses and major bleeding showed no difference between warfarin and control or between DAW and FDW. No survival difference was demonstrated in either comparison.

Interpretation: Thrombosis rates were low (5.3%); there is no benefit in using warfarin in comparison to no warfarin for the prophylaxis of symptomatic CRT or other thromboses in cancer patients.

Summary: 250 words
INTRODUCTION

Venous thromboembolism (VTE) is a well documented complication of cancer and may be linked to tumoral production of a range of procoagulant factors, certain chemo and hormone therapies and the use of central venous catheters (CVCs). Evidence of VTE is found at post mortem in around 50% of cancer patients\(^1\), but remains an under-diagnosed and under-treated condition in life. The last decade has seen an enormous increase in the use of CVCs to deliver infusional chemotherapy and, with this, recognition of catheter-related thrombosis (CRT) as a source of considerable morbidity\(^2\).

Hitherto, trials of thromboprophylaxis for adult cancer patients undergoing chemotherapy with CVCs have not produced a clear consensus on the role of anticoagulation. Differing definitions of CRT and inconsistent assessment of VTE have made comparisons problematic.

Two early influential studies in the 1990s addressed the potential of anticoagulants to reduce the incidence of thrombotic events\(^3,4\) and although small, suggested a benefit in using prophylactic anticoagulation, reducing thrombosis rates with minimal toxicity. However, trials since the turn of the century have challenged this thinking and have revealed no advantage of anticoagulant intervention in the reduction of thrombosis rates for patients having chemotherapy via CVCs\(^5,6,7,8\).

A survey of clinical opinion of thromboprophylaxis in patients receiving infusional chemotherapy via a CVC was undertaken in 1999 and informed the design of this study. Completed by over 200 UK cancer clinicians, the results indicated that 60% of clinicians used warfarin routinely as a thromboprophylactic (95% of these clinicians prescribed 1mg warfarin daily) and 20% of clinicians were certain of the indication
for warfarin intervention and hence would not be willing to randomise to a comparison with a ‘no warfarin’ arm.

This paper reports the outcome of a large open label, multicentre trial, investigating the utility of warfarin in thromboprophylaxis, in cancer patients with CVCs.

**Patients and Methods**

Sixty-eight UK clinical centres with nursing teams dedicated to catheter care participated in the trial. The centres received ethical approval from West Midlands Multi-Centre Research Ethics Committee and all patients consented in writing.

*Patient Eligibility*

Patient eligibility covered the following inclusion criteria: histologically confirmed diagnosis of cancer; requirement for CVC insertion for administration of chemotherapy; aged at least 16 years and with adequate hepatic, renal and haematological function. Exclusion criteria comprised: patients with a contraindication to warfarin; patients taking warfarin and pregnant or lactating women.

*Trial Design*

The study was structured to encompass contemporary clinical opinion noted from the pre-trial survey. Clinicians who were ‘uncertain’ of the benefits of warfarin in thromboprophylaxis, randomised patients to no warfarin (control) vs daily 1mg fixed dose warfarin (FDW) vs daily dose adjusted warfarin (DAW) to maintain the international normalised ratio (INR) between 1.5 and 2.0. Clinicians who were ‘certain’ of the indication for warfarin, randomised patients between FDW and DAW. All preferences were those of clinicians. Initially, the ‘uncertain indication’
preference had 3 arms, as previously described; however, investigators subsequently requested that a 2 arm option of control vs FDW be included (Figure 1). The trial design was amended accordingly by the Steering Committee after 141 patients had been randomised in the 3 arm comparison and 245 to the ‘certain’ preference. Randomisation was executed via a computerised block algorithm and accessed by telephone and fax. Stratification was based on three thrombosis risk factors: sclerosant potential of the cytotoxic regimen (low or high); site of placement of the catheter (peripheral or central); and duration of drug infusion (less than, or greater and equal to 24 hours; for duration of one chemotherapy cycle intravenous infusion).

This trial design enabled two key hypotheses to be tested: (i) whether warfarin reduces CRT relative to control (‘warfarin evaluation’ comparison) and (ii) whether DAW is superior to FDW (‘dose evaluation’ comparison).

Treatment Plan

All types of CVCs were permitted in the study; the correct position of the catheter tip (at the junction of the superior vena cava and the right atrium) was checked by chest X-ray post CVC insertion. Randomisation and start of warfarin, if allocated, was permitted from 3 days prior to CVC insertion (to enable sufficient exposure to warfarin for the immediate post insertion period). Warfarin was taken daily until thrombosis or catheter removal for any reason and could be temporarily discontinued in the face of thrombocytopenia (platelets≤50x10⁹/L). Agreed protocols for INR monitoring on all treatment arms were provided and treatment of VTE was carried out according to local practice.
Outcome Measures

The primary outcome measure reported is the incidence of radiologically confirmed symptomatic catheter-related thrombotic events, i.e. occurring in the venous system draining the catheter, or pulmonary emboli (PE) in patients who had catheter complications. Secondary outcome measures include non catheter-related thrombotic events (occurring in the arterial system, in the venous system not draining the catheter and PE in patients with no catheter complications), catheter patency, warfarin-related adverse events (bleeding and raised INR), overall survival, catheter-related infections and health service related costs (not reported here). All thromboses were radiologically confirmed by venogram, ultrasound or ventilation-perfusion (VQ) / Spiral CT and classified as CRT or non-CRT by two investigators, blinded to treatment allocation, using a central protocol. Thromboses that were suspected but not radiologically confirmed were recorded under CVC complications. Major bleeding episodes were defined as intracranial, retroperitoneal, requiring transfusion or hospitalisation or directly leading to death. Increased INR was classified by the investigators as: mild (2<INR<5), moderate (5≤INR<8) or severe (INR≥8). Dates of death were obtained from the case record forms or from the Office of National Statistics (ONS) in April 2007.

Statistical methods

Sample size calculations were made on the following assumptions: the thrombotic event rate for patients on no warfarin was around 25% and if warfarin were to reduce this rate by 10%, this would be a medically worthwhile improvement. With 800
patients entered into the uncertain indication (400 no warfarin and 400 warfarin), there would be >90% power to detect a 10% difference. With 1000 patients randomised between warfarin doses, there would be 80% power to detect a difference of 7% in thrombotic event rates between the two dosing schedules. The trial had approximately 90% power to detect a 10% difference in long term survival comparing warfarin and no warfarin groups.

Rates of thrombotic events were compared using Mantel-Haenszel chi-square tests, stratified by randomisation option. Differences between treatments are expressed as relative risk (RR) with 95% confidence intervals (CI). The analysis was carried out on an intention-to-treat basis, with a small number of ‘unknown outcome’ patients combined with those not experiencing an event. Sensitivity analysis confirmed the validity of the assumption. CRT events were also analysed as time to event data with time to thrombosis censored at date of CVC removal in those with no event. In addition, time to thrombosis in patients with an event was compared using Wilcoxon tests. Duration of catheter patency was calculated as time from catheter insertion to thrombotic event or CVC complication and censored at CVC removal for those patients with no event. Overall survival, measured from date of randomisation to date of death or date last seen alive, was analysed using Kaplan-Meier estimation and log-rank tests. Major bleeding episodes were compared using Fisher’s Exact test. All p-values are two-sided.

Role of the Funding Source
The Medical Research Council and Cancer Research UK funded the salaries of the WARP clinical research fellow and data manager respectively; they had no involvement in the trial or publication.
RESULTS

WARP recruited 1590 patients between October 1999 and December 2004; 812 were randomised to the ‘uncertain’ preference (404 to control, 408 to warfarin) and 778 to the ‘certain’ preference (389 to FDW and 389 to DAW). The design enabled 166 (10.4%) patients to contribute to both comparisons. Due to inclusion of the ‘uncertain’ indication 2-arm option (control vs FDW), of those patients randomised to the warfarin arm of the control comparison, 324 (79.4%) patients received FDW daily and 84 (20.6%) received DAW daily (Figure 1).

Patient and CVC characteristics

Baseline patient and CVC characteristics (Table 1) and are well balanced across the study arms. Peripherally inserted central catheters (PICCs) were used for 58% of patients, in keeping with a rising trend in practice. Patients were similar with respect to age, treatment length, performance status, disease site and stage of disease across all arms. 93% of patients had World Health Organisation (WHO) Performance Status of 0 and 1, although 65% had advanced disease; over 50% of patients presented with colorectal cancer.
Compliance

Protocol Compliance

Of 1590 patients, four were found to be ineligible, three on clinical parameters and one declining chemotherapy immediately post randomisation. Four additional patients did not have CVCs inserted post randomisation. Twelve further patients did not receive any allocated warfarin treatment (eight on warfarin 1mg and four on DAW), mostly due to patient choice. All were included in the analysis.

Warfarin Compliance

Of the 1139 patients who started warfarin, 26 (2.3%) patients and/or their clinicians did not conform to warfarin dose. Of these, for the five patients allocated FDW, the clinician chose to prescribe the variable dose; twenty out of 21 patients on DAW took 1mg warfarin daily either in error or by choice.

The protocol stated that warfarin should be taken until catheter removal or thrombosis; only 155 (10%) of patients started warfarin 3 days prior to catheter insertion and of the 1139 patients starting warfarin, 106 (9%) stopped ‘early’ (more than 7 days before the catheter was removed), largely due to their chemotherapy being completed and the CVC was still in situ but also because of patient choice or thrombocytopenia; this was balanced across treatment arms. Data on warfarin compliance were incomplete on 8% of patients.

The CONSORT diagram, available on-line, shows detailed compliance data.
**Thrombotic events**

Of the 1590 patients randomised, 85 (5.3%) had a radiologically confirmed CRT event. There were also 9 clinically suspected thromboses, not confirmed radiologically and classified as CVC complications. Warfarin (of which 79% was FDW) did not reduce the incidence of CRT relative to control (24 (5.9%) vs 24 (5.9%); RR=0.99, 95%CI 0.57–1.72, p=0.98) (Table 2a). In contrast, there were significantly fewer CRT in those patients allocated DAW compared to FDW (13 (2.8%) vs 34 (7.2%); RR=0.38; 95%CI 0.20–0.71, p=0.002). Analysis of this primary outcome as time-to-event data showed comparable results (Figure 2). A further 36 (2.3%) patients had a non-CRT event. Neither warfarin (compared to control) nor DAW (compared to FDW) have any significant impact (p=0.30 and p=0.15 respectively) on all thrombotic events (Table 2a). Comparisons of the FDW and DAW groups separately with control are shown in Table 3 – there are no significant differences.

The location of the 85 CRT were reported as follows: 32 upper limb, 17 axillary vein, 16 subclavian vein, 10 internal jugular, 4 superior vena cava, 2 pulmonary emboli, 2 catheter and 2 with site not stated. The location of the 36 non-CRT events presented as 18 lower limb, 9 pulmonary emboli, 4 upper limb, 2 inferior vena cava, 1 subclavian vein, 1 pulmonary vein and 1 portal vein. Non-CRT events were all venous with the exception of one upper limb arterial thrombosis.
**Time to Thrombosis, Catheter – Patency and Infections**

For the 85 patients with a CRT, median time to CRT was 32 days from randomisation (IQR=13 to 76 days). Median time to CRT did not significantly differ in the warfarin vs control (25 vs 32 days, p=0.71), or DAW vs FDW (60 vs 31 days, p=0.51) comparisons. Median time to all 121 thromboses (CRT and non-CRT) was 44 days (IQR=13-84 days). CVCs were patent for a median time of 13.9 weeks for all patients. There was no significant difference in the median duration of catheter patency across treatments. 124 patients (7.8%) were categorised as having one or more catheter-related infections; there were no significant differences between treatments.

**Major bleeding and INR**

There was some evidence of an excess of major bleeding events in patients on warfarin vs control (RR=6.93, 95%CI 0.86-56.08, p=0.07) and in patients on DAW vs FDW (RR=2.28, 95%CI 0.95-5.48, p=0.09), although both failed to reach statistical significance. An increase in moderately and severely raised INR without major bleeding was also demonstrated (Table 2b). According to participating clinicians, warfarin may have contributed to the deaths of two patients receiving DAW; no thrombosis was reported as contributing to death. Given the fine balance between the clinical consequences of thrombosis and major bleeding, we examined a combined endpoint of thrombotic events plus major bleeds. This analysis revealed no significant difference between treatment arms for both comparisons (Table 2c).
Detailed INR readings were analysed from one centre with 54 patients on FDW and 56 patients on DAW. INR determinations were taken on average, 6 times for FDW and 19 times for DAW groups over a median timespan of 1.8 months and 5.1 months respectively. Median INR for FDW group was 1.10, (IQR 1.04-1.24); for DAW group was 1.69, (IQR 1.43-1.93).

**Overall Survival**

At the time of analysis, 532 patients were still alive with a median follow-up of 45 months (range 26 to 88 months). Of the 1058 reported deaths, 921 (87%) were due to cancer; 53 (5%), other causes; and 84 (8%), cause unknown. No overall survival advantage was found from taking warfarin compared to control (HR=0.98, 95%CI: 0.77-1.25, p=0.26) or found between the two dosing schedules (HR=0.91, 95% CI 0.73-1.14, p=0.53) (Figure 3).

**Discussion**

This trial demonstrates that warfarin (79% FDW, 21% DAW) does not have a useful role in the prophylaxis of CRT. The overall incidence of symptomatic CRT was relatively low (5.3%), in keeping with a general temporal trend brought about by improved catheter design and care. It is interesting to note that more clinicians than expected from the pre-trial survey were ‘certain’ of the indication for warfarin; they may have been influenced by the results of early studies and some were also high recruiters. When compared to control, warfarinisation does not offer any advantage in reducing CRT. Similarly, warfarin did not reduce the incidence of all thrombotic events or have any impact on survival. When FDW and DAW
respectively were compared directly with the control arm, there was no advantage demonstrated from either warfarin dose; however, the numbers in each arm are small (Table 3). Conversely, when compared to FDW, DAW did significantly reduce the number of symptomatic CRT but at an increased cost in terms of major bleeds and additional INR monitoring. This reduction in CRT events with DAW over FDW does not translate into a decrease in all thrombotic events and, in effect, is cancelled out when the combined endpoint of thrombosis plus major bleeding is observed. However, for clinicians still wishing to offer prophylactic oral anticoagulation to patients with CVCs, for example, those at high thrombotic risk and who are prepared to accept the related toxicity profile, dose adjusted warfarin may be the more logical choice. Exploratory subgroup analysis will be the topic of a future paper.

Our findings are in keeping with the results of more recent studies on thromboprophylaxis in cancer patients with CVC. Bern et al (1990) compared 1 mg warfarin for 90 days to control in cancer patients with long term central venous catheters. VTE were detected symptomatically and by routine venogram in 15 of 40 (37.5%) control patients in comparison to 4 of the 42 (9.5%) patients on warfarin (p<0.001). Monreal et al (1996) randomised a similar group of patients to the low molecular weight heparin (LMWH), dalteparin (2500iu subcutaneously, daily for 90 days) or control. Early trial closure was precipitated by differential upper limb thrombosis rates (1/16 dalteparin arm vs 8/13 in control patients, p=0.002), confirmed by routine venography. A Korean group, in 1999, randomised 80 cancer patients with CVCs to 1mg warfarin vs control and reported thrombosis rates of 13% vs 29% respectively (p=0.07). Although small, these three trials suggested a
benefit in using prophylactic anticoagulation by reducing thrombosis rates with minimal toxicity. However, more recent trials have found no benefit from warfarin intervention. Heaton et al (2002) examined the effects of 1mg fixed daily dose of warfarin versus control on thromboprophylaxis in 88 haemato-oncology patients receiving chemotherapy via CVCs. No significant difference in symptomatic thromboses (18% vs 12% respectively, p=0.4) was demonstrated. Similarly, Couban and colleagues recorded the number of symptomatic thrombotic events in a trial of 255 patients (80% with haematological malignancies) receiving warfarin 1mg or placebo for 9 weeks. Overall CRT rates were low; 4.6% with warfarin and 4.0% with placebo (HR, 1.2, 95% CI, 0.37 – 3.94). It appears more difficult to keep cancer patients on warfarin within target INR range. Our INR analysis showed a similar variability to other studies. INR monitoring of patients receiving DAW was problematic in some centres.

LMWHs recently evaluated in trials, have also proven no more effective than control in the prophylaxis of CRT. Verso et al adopted a primary endpoint of thrombosis (measured at routine investigation) in a trial of enoxaparin (40mg once daily for 6 weeks) vs placebo. In 385 cancer patients, thrombosis rates were found to be similar in both arms (14% enoxaparin vs 18% placebo, p=0.35). Karthaus and colleagues showed no symptomatic thromboprophylactic effect of dalteparin (5000iu/day) in comparison to placebo (3.7% and 3.4% respectively, p=0.88). Our results concur both with a recent pooled estimate of the Bern and Heaton trials, confirming a lack of benefit from warfarin. When WARP data were added to a previous meta-analysis of warfarin intervention vs control in the prophylaxis of thrombosis in cancer patients with CVCs, the earlier advantage seen for warfarin
(OR 0.58, CI 0.34-1.01; p=0.05) was reduced (OR 0.75, CI 0.5-1.1; p=0.1) (Figure 4).

Taking these trials in concert with this definitive report, it is noticeable that the incidence of symptomatic CRT reported in clinical trials has markedly declined over the past decade\textsuperscript{12}. The improvements in catheter technology, placement and aftercare are contributing to this reduction\textsuperscript{13,14}. The clinically relevant benefit/risk outcome of (prophylaxis of) thrombotic events plus major bleeding demonstrated no advantage in using any dose of warfarin. These findings only add to the assertion, ‘it is time to move on from warfarin’ for thromboprophylaxis in the cancer patient population.

MANUSCRIPT: 2995 WORDS
### Table 1: Baseline Patient Characteristics

<table>
<thead>
<tr>
<th>Factor</th>
<th>Control</th>
<th>Dose evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Warfarin N (%): U3*: N=166 U2*: N=242</td>
<td>FDW N (%): U3*: N=82 C2*: N=389</td>
</tr>
<tr>
<td>Factor</td>
<td>Grouping</td>
<td>comparison</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>Median (IQR) 61 (53-68)</td>
<td>60 (53-68)</td>
</tr>
<tr>
<td>WHO Performance Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>221 (55%)</td>
<td>263 (56%)</td>
</tr>
<tr>
<td>1</td>
<td>168 (42%)</td>
<td>178 (38%)</td>
</tr>
<tr>
<td>2/3</td>
<td>10 (2%)</td>
<td>23 (5%)</td>
</tr>
<tr>
<td>Not known</td>
<td>5 (1%)</td>
<td>7 (1%)</td>
</tr>
<tr>
<td>Stage of disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No residual/early</td>
<td>130 (32%)</td>
<td>171 (36%)</td>
</tr>
<tr>
<td>Advanced</td>
<td>273 (68%)</td>
<td>294 (62%)</td>
</tr>
<tr>
<td>Not known</td>
<td>1 (0.3%)</td>
<td>6 (1%)</td>
</tr>
<tr>
<td>Disease site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td>201 (50%)</td>
<td>226 (48%)</td>
</tr>
<tr>
<td>Upper GI</td>
<td>109 (27%)</td>
<td>95 (20%)</td>
</tr>
<tr>
<td>Breast</td>
<td>32 (8%)</td>
<td>82 (17%)</td>
</tr>
<tr>
<td>Other</td>
<td>50 (12%)</td>
<td>52 (11%)</td>
</tr>
<tr>
<td>Not known</td>
<td>12 (3%)</td>
<td>16 (3%)</td>
</tr>
<tr>
<td>Catheter Placement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central</td>
<td>146 (36%)</td>
<td>226 (48%)</td>
</tr>
<tr>
<td>Peripheral</td>
<td>258 (64%)</td>
<td>228 (48%)</td>
</tr>
<tr>
<td>Sclerosant potential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-sclerosant</td>
<td>172 (43%)</td>
<td>235 (50%)</td>
</tr>
<tr>
<td>Sclerosant</td>
<td>232 (57%)</td>
<td>236 (50%)</td>
</tr>
<tr>
<td>Treatment length</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24 hours</td>
<td>64 (16%)</td>
<td>87 (18%)</td>
</tr>
<tr>
<td>≥24 hours</td>
<td>340 (84%)</td>
<td>384 (82%)</td>
</tr>
</tbody>
</table>

*U = Uncertain Indication for Warfarin; C= Certain Indication for Warfarin; 3= 3 arm; 2= 2 arm
Table 2a: Thrombotic Events*

<table>
<thead>
<tr>
<th></th>
<th>Warfarin Evaluation</th>
<th></th>
<th>Dose Evaluation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No Warfarin (N=404)</td>
<td>Warfarin (N=408)</td>
<td>Relative Risk</td>
<td>FDW (N=471)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(95% CI)</td>
<td></td>
</tr>
<tr>
<td>Relative Risk</td>
<td>0.99 (0.57, 1.72)</td>
<td>0.78 (0.50, 1.24)</td>
<td>0.38 (0.20, 0.71)</td>
<td>0.38 (0.20, 0.71)</td>
</tr>
<tr>
<td>p-value</td>
<td>0.98</td>
<td>0.30</td>
<td>0.002</td>
<td>0.002</td>
</tr>
<tr>
<td>CRT Events</td>
<td>24 (5.9%)</td>
<td>24 (5.9%)</td>
<td></td>
<td>34 (7.2%)</td>
</tr>
<tr>
<td>No event</td>
<td>370 (91.6%)</td>
<td>372 (91.2%)</td>
<td></td>
<td>433 (91.9%)</td>
</tr>
<tr>
<td>Not known</td>
<td>10 (2.5%)</td>
<td>12 (2.9%)</td>
<td></td>
<td>4 (0.9%)</td>
</tr>
<tr>
<td>All thrombotic events</td>
<td>38 (9.4%)</td>
<td>30 (7.4%)</td>
<td>0.78 (0.50, 1.24)</td>
<td>37 (7.9%)</td>
</tr>
<tr>
<td>(CRT&amp; non-CRT)</td>
<td></td>
<td></td>
<td>p=0.30</td>
<td></td>
</tr>
<tr>
<td>No event</td>
<td>356 (88.1%)</td>
<td>368 (90.2%)</td>
<td></td>
<td>430 (91.3%)</td>
</tr>
<tr>
<td>Not known</td>
<td>10 (2.5%)</td>
<td>12 (2.9%)</td>
<td></td>
<td>4 (0.9%)</td>
</tr>
</tbody>
</table>

Table 2b: Bleeding and raised INR (moderate and severe)

| Major Bleeding & no reported raised INR | 1 | 3 | 5 | 7 |
| Major Bleeding & raised INR             | 0 | 4 | 2 | 9 |
| Total Major Bleeding                    | 1 (0.3%) | 7 (1.7%) | 6.93 (0.86, 56.08) | 7 (1.5%) | 16 (3.4%) | 2.28 (0.95, 5.48) |
| p-value                                 | 0.07 | 0.09 |
| Moderate and severe raised INR & no major bleeding | 0 | 3 | 1 | 12 |

Table 2c: Combined Thrombosis Major and Bleeding

| CRT Events | 24 | 24 | 34 | 13 |
| Total Major Bleeding | 1 | 7 | 1.23 (0.83, 1.52) | 7 | 16 |
| Total | 25 (6.2%) | 31 (7.6%) | 41 (8.7%) | 29 (6.1%) | 0.84 (0.74, 2.04) |
| p-value | 0.51 | 0.17 |
| All thrombotic events (CRT & non-CRT) | 38 | 30 | 37 | 26 |
| Total Major Bleeding | 1 | 7 | 0.94 (0.61, 1.44) | 7 | 16 |
| Total | 39 (9.7%) | 37 (9.1%) | 44 (9.3%) | 42 (8.9%) | 0.95 (0.64, 1.42) |
| p-value | 0.87 | 0.89 |
## Table 3: Thrombotic Events – Other Randomised Comparisons

<table>
<thead>
<tr>
<th>Event Type</th>
<th>Control vs FDW</th>
<th>Control vs DAW*</th>
<th>Relative Risk (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRT Events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRT Events (No Warfarin)</td>
<td>24 (5.9%)</td>
<td>22 (6.8%)</td>
<td>1.10 (0.64, 1.89)</td>
<td>p=0.72</td>
</tr>
<tr>
<td>CRT Events (DAW)</td>
<td>5 (3.1%)</td>
<td>2 (2.4%)</td>
<td>0.77 (0.15, 3.87)</td>
<td>p&gt;0.99</td>
</tr>
<tr>
<td>All thrombotic events (CRT &amp; non-CRT)</td>
<td>38 (9.4%)</td>
<td>28 (8.6%)</td>
<td>0.91 (0.57, 1.45)</td>
<td>p=0.69</td>
</tr>
<tr>
<td>All thrombotic events (CRT &amp; non-CRT)</td>
<td>13 (8.1%)</td>
<td>2 (2.4%)</td>
<td>0.29 (0.07, 1.28)</td>
<td>p=0.10</td>
</tr>
<tr>
<td>Major Bleeding</td>
<td>1 (0.3%)</td>
<td>3 (0.9%)</td>
<td>3.74 (0.39, 35.79)</td>
<td>p=0.33</td>
</tr>
<tr>
<td>Total major bleeding and CRT events</td>
<td>25 (6.2%)</td>
<td>25 (7.7%)</td>
<td>1.25 (0.73, 2.13)</td>
<td>p=0.51</td>
</tr>
<tr>
<td>Total major bleeding and all thrombotic events</td>
<td>39 (9.7%)</td>
<td>31 (9.6%)</td>
<td>0.99 (0.63, 1.55)</td>
<td>p&gt;0.99</td>
</tr>
</tbody>
</table>
Figure 1 – Trial Flow Diagram

Figure 1 - Trial Structure at Randomisation

Are you (clinician) certain or uncertain of the benefits of warfarin in the prophylaxis of thrombosis in cancer patients with CVCs?

Uncertain  
n=812

Are you (clinician) willing to participate in the dose adjusted warfarin (DAW) arm?

YES – 3 arm study  
n=327

1mg warfarin od*  
n=82  
CRT - 8

DAW warfarin od*  
n=84  
CRT - 2

No warfarin  
n=161  
CRT - 5

NO – 2 arm study  
n=485

1mg warfarin od*  
n=242  
CRT - 19

DAW warfarin od*  
n=243  
CRT - 11

1mg warfarin od*  
n=389  
CRT - 13

1mg warfarin od*  
n=389  
CRT - 26

2 parallel randomised studies:

No warfarin  
n=404  
(161+243)  
CRT - 24

Warfarin  
n=408  
(242+82+84)  
FDW; n=324

DAW; n=84

1mg warfarin  
n=471  
(82+389)  
CRT - 34

DAW warfarin  
n=473  
(84+389)  
CRT - 13

* once daily:  
CRT – Catheter-related thromboses
Figure 2 – Time to Thrombosis

2a) Time to Thrombosis – Control vs Warfarin

Log-rank p = 0.95

2b) Time to Thrombosis – FDW vs DAW

Log-rank p = 0.002
Figure 3: Overall survival

3a) Overall Survival - Control vs Warfarin

3b) Overall Survival - FDW vs DAW
Figure 4

Meta-analysis of prevention of thrombosis with warfarin vs control in cancer patients with CVCs

<table>
<thead>
<tr>
<th>Previous trials:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin</td>
</tr>
<tr>
<td>Bern (1990)</td>
</tr>
<tr>
<td>Park (1999)</td>
</tr>
<tr>
<td>Heaton (2002)</td>
</tr>
<tr>
<td>Couban (2005)</td>
</tr>
<tr>
<td><strong>Subtotal:</strong></td>
</tr>
<tr>
<td><strong>Total:</strong></td>
</tr>
</tbody>
</table>

Test for heterogeneity between subgroups: $X^2_3 = 7·4; P = 0·06$

**WARP:**

<table>
<thead>
<tr>
<th>Warfarin</th>
<th>Control</th>
<th>(O−E)</th>
<th>Var.</th>
<th>O.R. &amp; 95% CI (Warfarin : Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young</td>
<td>24/408</td>
<td>24/404</td>
<td>−0·1</td>
<td>11·3</td>
</tr>
<tr>
<td>Total:</td>
<td>47/682</td>
<td>61/674</td>
<td>−7·1</td>
<td>24·2</td>
</tr>
</tbody>
</table>

Test for heterogeneity (5 trials): $X^2_4 = 9·1; P = 0·06$

Test for heterogeneity between subtotals: $X^2_1 = 1·7; P = 0·2; NS$
References:


21. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved
List of tables and figures

Table 1: Baseline Patient Characteristics
Table 2a: Thrombotic Events
Table 2b: Major Bleeding and raised INR (moderate and severe)
Table 2c: Combined CRT and Major Bleeding
Table 3: Thrombotic Events – Additional Randomised Comparisons

Figure 1: Trial Flow Diagram
Figure 2: Time to Thrombosis
   2a) Time to Thrombosis – Control vs Warfarin
   2d) Time to Thrombosis – FDW vs DAW

Figure 3: Overall Survival
   3a) Overall Survival - Control vs Warfarin
   3b) Overall Survival - FDW vs DAW

Figure 4: Meta-analysis of prevention of thrombosis with warfarin vs control in cancer patients with CVCs
Authors’ contributions statement

All authors contributed to the writing of the manuscript and the Cancer Research UK Clinical Trials Unit, University of Birmingham vouches for the accuracy and completeness of the data and analysis.

Conflict of interest statement

There are no known conflicts of interest.

Source of funding statements

The funding for the WARP trial was provided by a Medical Research Council Clinical Research Fellowship and by Cancer Research UK.

Acknowledgements:

To the Medical Research Council for clinical research fellowship funding and Cancer Research UK for data management funding.